U.S. Markets close in 2 hrs 54 mins

3 Reasons Why Corvus Pharmaceuticals (CRVS) is a Great Momentum Stock

Zacks Equity Research

Many investors like to look for momentum in stocks, but this can be very tough to define. There is great debate regarding which metrics are the best to focus on in this regard, and which are not really quality indicators of future performance. Fortunately, with our new style score system we have identified the key statistics to pay close attention to and thus which stocks might be the best for momentum investors in the near term.

This method discovered several great candidates for momentum-oriented investors, but today let’s focus in on Corvus Pharmaceuticals, Inc. CRVS as this stock is looking especially impressive right now. And while there are numerous ways in which this company could be a great choice, we have highlighted three of the most vital reasons for CRVS’s status as a solid momentum stock below:

Longer Term Price Change for Corvus Pharmaceuticals

While any stock can see a spike in price, it takes a real winner to consistently outperform the market. That is why looking at longer term price metrics—such as performance over the past three months or year-- and comparing these to an industry at large can be very useful.

And in the case of CRVS, the results are quite impressive. The company has beaten out the industry at large over the past 12 weeks by a margin of 39.6% to 1.2% while it has also outperformed when looking at the past year, putting up a gain of 42.5%. Clearly, CRVS is riding a bit of a hot streak and is worth a closer look by investors.

Corvus Pharmaceuticals, Inc. Price

Corvus Pharmaceuticals, Inc. Price | Corvus Pharmaceuticals, Inc. Quote

Fiscal Year EPS Estimate Change for CRVS

In addition to price performance, it is also important to take a look at earnings estimate changes for the full year. This can show if CRVS is poised to make a run based on fundamentals, or if the company is simply moving on speculation.

Over the past month, the full year earnings estimate for CRVS has risen by 8%. On its own this is impressive, but consider that it also beats the industry average of 0% too. The trend is undeniably in Corvus Pharmaceuticals’ favor right now, and it suggests that the momentum might be long lasting for this stock.

Earnings Estimate Revisions Moving in the Right Direction

While the great momentum factors outlined in the preceding paragraphs might be enough for some investors, we should also take into account broad earnings estimate revision trends. A nice path here can really help to show us a promising stock, and we have actually been seeing that with CRVS as of late too.

Over the past two months, one earnings estimate has gone higher compared to none lower for the full year. This revision have helped to boost the consensus estimate as two months ago CRVS was expected to post a loss of $3.64 per share for the full year, though today it looks to post a loss of $3.35 for the full year, representing an increase which is something that should definitely be welcomed news to would-be investors.

Bottom Line

Given these factors, investors shouldn’t be surprised to note that we have CRVS as a security with a Zacks Rank #1 (Strong Buy) and a Momentum Score of ‘A’. You can see the complete list of today’s Zacks #1 Rank stocks here.

So if you are looking for a fresh pick that has potential to move in the right direction, definitely keep CRVS on your short list as this looks be a stock that is very well-positioned to soar in the near term.

Zacks’ Best Private Investment Ideas

While we are happy to share many articles like this on the website, our best recommendations and most in-depth research are not available to the public.

Starting today, for the next month, you can follow all Zacks' private buys and sells in real time. Our experts cover all kinds of trades… from value to momentum . . . from stocks under $10 to ETF and option moves . . . from stocks that corporate insiders are buying up to companies that are about to report positive earnings surprises. You can even look inside exclusive portfolios that are normally closed to new investors. Click here for Zacks' private trades >>


Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
 
Corvus Pharmaceuticals, Inc. (CRVS): Free Stock Analysis Report
 
To read this article on Zacks.com click here.
 
Zacks Investment Research